Angelo Antonini, MD, PhD, is a renowned Professor of Neurology at the University of Padua, Italy. After graduating in medicine from The Sapienza University of Rome, Prof. Antonini remained in Rome to complete specialist neurology training, where he focused on neuropharmacology and movement disorders. He then went on to complete a PhD in neuroradiology at the University of Zurich in Switzerland. Continuing his research in neuroimaging and movement disorders, Prof. Antonini undertook a position at the NY Shore University Hospital and became Assistant Professor of Neurology at New York University. Since returning to Italy in 1997, Prof. Antonini has worked as Assistant Professor at the University of Milano-Bicocca and Head of Clinical Research for Parkinson’s disease at the University Hospital. He then headed the unit for Parkinson’s disease and movement disorders at the National Research Institute San Camillo Venice, before taking on his current role at the Neurology Clinic of the University Hospital in Padua. He was awarded full professorship at the University of Padua in 2013.
Throughout his impressive academic career, Prof. Antonini has contributed extensively to progress in the field of movement disorders, publishing over 400 articles, reviews, and book chapters. A major force in the research space, he has been an invited speaker at top neurology congresses worldwide, teaches at the School of Medicine and the School of Psychology at the University of Padua, and is a reviewer for numerous major neurological journals. Prof. Antonini is the current President of the European Section of the Movement Disorders Society (MDS) and Co-Chair of the Movement Disorders Panel of the European Academy of Neurology (EAN).
Speaking on neurology, neuroradiology, and neuroscience in Parkinson’s disease
Prof Antonini’s research focuses on movement disorders, particularly Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. His interests lie in neuroimaging, neuropharmacology, and the treatment and management of Parkinson’s disease. He is also dedicated to developing evidence based palliative care guidelines, working as a member of the MDS task force on palliative care. His recent work has investigated the use of continuous infusion of levodopa and apomorphine as well as subthalamic stimulation for the treatment of motor complications in Parkinson’s.